Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 10 mg; valsartan, quantity: 320.001 mg - tablet - excipient ingredients: macrogol 8000; silicon dioxide; hyprolose; purified water; iron oxide yellow; calcium hydrogen phosphate; titanium dioxide; aluminium magnesium silicate; powdered cellulose; hypromellose; purified talc; magnesium stearate; croscarmellose sodium - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 10 mg; valsartan, quantity: 320.001 mg - tablet - excipient ingredients: powdered cellulose; titanium dioxide; croscarmellose sodium; silicon dioxide; hyprolose; purified water; purified talc; macrogol 8000; calcium hydrogen phosphate; aluminium magnesium silicate; iron oxide yellow; magnesium stearate; hypromellose - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 160 mg - valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection,

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 5 mg

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - amlodipine 5 mg - exforge hct (amlodipine, valsartan, and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with exforge hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high b

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10 mg/ 160mg/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/320/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 5 mg/160 mg/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 5 mg/160 mg/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide